Aileron to Leverage Scripps’ Click Chemistry to Develop Peptide and Protein...

Click chemistry joins small reactive molecular building blocks together to drive binding reactions.

Genentech Acquires Preclinical Human IL-17 mAb from NovImmune

Deal for anti-inflammatory candidate includes access to back-up antibodies.

The Therapeutic Antibody Screening Revolution in the Post Genomics Era

In this GEN webinar, sponsored by Carterra, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.

Cleanliness is Next to Ineffectiveness…of Antibiotics

The hygiene hypothesis—or more recently dubbed microbiome depletion theory—is a supposition proposed in the late 1980s from the observation that children in larger family...

Novel Chip Developed to Detect Antibiotic-Resistant Bacteria in an Hour

University of Toronto devise electrochemical phenotyping approach to rapidly detect antibiotic-resistant bacteria.

Alga Provides Feasible Mass Production System for Subunit Malaria Vaccine Candidate

Mice injected with recombinant Pfs25 protein generate parasite transmission-blocking antibodies.

Artificial Intelligence Makes Worms More Informative

Scientists have developed a high-throughput artificial intelligence-based imaging technique that can automatically screen for subtle morphological changes associated with genetic manipulation in Caenorhabditis elegans nematodes.

RNAi Therapy for Preeclampsia is Pregnant with Possibility

RNAi decreases expression of sFLT1, the cause of preeclampsia symptoms, establishing a potential strategy for the treatment of preterm preeclampsia.

Merck & Co. Launches Up-to-$2.5B Cancer Collaboration with Taiho, Astex

Merck & Co. will partner with Taiho Pharmaceutical and Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical, to develop small molecule inhibitors against the KRAS oncogene and several other drug targets under study as potential cancer treatments, through a collaboration that could generate more than $2.5 billion for Taiho and Astex.

Endocyte Refocuses Development on Prostate Cancer Radioligand Therapeutic

Endocyte has licensed ABX’s radioligand therapeutic (RLT) candidate PSMA-617 in a deal that could generate up to $172 million-plus for the German nuclear medicine company, adding that it will refocus the company’s development efforts around the prostate cancer treatment.
Scroll Up